Navigation Links
Aratana Therapeutics to Report Second Quarter 2013 Financial Results
Date:7/23/2013

KANSAS CITY, Kan. and BOSTON, July 23, 2013 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative prescription medications for pets, will host a conference call and live audio webcast on Tuesday, August 13, 2013, at 8:00 a.m. ET to discuss its financial results for the quarter ended June 30, 2013, and to provide an update on its pet therapeutics development programs.

Interested participants and investors may access the conference call by dialing (800) 860-2442 (U.S.), (866) 605-3852 (Canada), or (412) 858-4600 (international). An audio webcast will be accessible via the Investors Relations section of the Aratana Therapeutics website aratana.investorroom.com.  

A replay of the call will be available for 90 days beginning at approximately 10:00 a.m. ET on August 13, 2013. Access numbers for this replay are (877) 344-7529 (U.S./Canada) and (412) 317-0088 (international); conference ID: 10031855. The webcast replay will remain available in the Investors Relations section of the Aratana Therapeutics website for 90 days.

About Aratana Therapeutics
Aratana Therapeutics is a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative prescription medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana's strategy is to in-license proprietary compounds from human biopharmaceutical companies and to develop these product candidates into regulatory-approved therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.  For more information, please visit www.aratana.com.

Contacts:
Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D. (Investors)
jdrumm@tiberend.com; (212) 375-2664

Andrew Mielach (Media)
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Aratana Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Aratana Therapeutics Announces Full Exercise of Over-Allotment Option
2. Aratana Therapeutics Adds To Drug Development Team
3. Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
4. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
5. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
6. Aratana Therapeutics Completes $15 Million Series B Financing
7. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
8. United Therapeutics Corporation to Announce Second Quarter 2013 Financial Results Before Market Open on Thursday, July 25, 2013
9. Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories, and Star Scientific
10. Sorrento Therapeutics Presents Preclinical Data of its Fully Human Antibody Programs Targeting Anti-PD-L1 and Anti-PD-1 at the 8th Annual Next Generation Protein Therapeutics Summit
11. Frost & Sullivan Presents bitop AG with the 2013 New Product Innovation Award in the Extremolytes Therapeutics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... The ... Center in Atlanta, Georgia, will include 848 exhibitors (count as of February 9) ... displaying products and services used by the scientific community in industrial, academic, and ...
(Date:2/12/2016)... PLAINFIELD, N.J. , Feb. 12, 2016 /PRNewswire/ ... announced the second annual STRIVE (Strategies to Realize ... Duchenne muscular dystrophy (DMD). STRIVE provides funds to ... programs that will make meaningful contributions to the ... or fostering development of future patient advocates. ...
(Date:2/11/2016)... , February 11, 2016 Non-profit Consortium ... Genetic Understanding to Support Research and Discovery ... today announced an ambitious plan to sequence 100,000 individuals. It ... countries and at least 7 of North and East Asian ... the first phase, the project will focus on creating phased ...
(Date:2/11/2016)... AUSTIN, Texas , Feb. 11, 2016  Vermillion, ... focused on gynecologic disease, today announced the formation of ... --> --> Pelvic ... in both diagnosis and management. Once pregnancy is ruled ... fallopian tubes and ovaries, advanced endometriosis, benign ovarian tumors ...
Breaking Biology Technology:
(Date:2/3/2016)... --> --> ... Fingerprint Identification System Market by Component (Hardware and Software), ... Finance, Government, Healthcare, and Transportation) and Geography - Global ... expected to be worth USD 8.49 Billion by 2020 ... 2020. The transformation and technology evolution from the manual ...
(Date:2/2/2016)... , Feb. 2, 2016 This ... the bioinformatic market by reviewing the recent advances ... tools that drive the field forward. Includes forecast ... Identify the challenges and opportunities that exist ... and software solution developers, as well as IT ...
(Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
Breaking Biology News(10 mins):